Study shows ritonavir-boosted nirmatrelvir remains effective against new omicron variants in the U.S Post author: Post published:February 13, 2024 Post category:uncategorized The effectiveness of ritonavir-boosted nirmatrelvir (NMV-r) against Omicron variants. You Might Also Like PD-1 deficiency reveals the impact of checkpoint inhibition on B cell function November 27, 2024 Research sheds light on how hypoxia affects T cell function in cancer December 14, 2024 Long-term study shows peanut patch treatment builds tolerance in toddlers November 6, 2025